<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027885</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU3100</org_study_id>
    <secondary_id>U01CA062502</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-3100</secondary_id>
    <secondary_id>NCI-2722</secondary_id>
    <nct_id>NCT00027885</nct_id>
  </id_info>
  <brief_title>Phase II Bevacizumab + Tax In Advanced Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Bevacizumab in Combination With Docetaxel in Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block&#xD;
      cancer growth in different ways. Some block the ability of cancer cells to grow and spread.&#xD;
      Others find cancer cells and help kill them or deliver cancer-killing substances to them.&#xD;
      Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is to see if docetaxel with or without bevacizumab&#xD;
      followed by surgery, radiation therapy, and combination chemotherapy works better in treating&#xD;
      patients who have stage III or stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effect of bevacizumab and docetaxel on reduction of microvessel density&#xD;
           and induction of apoptosis of endothelial and tumor cells in patients with locally&#xD;
           advanced breast cancer.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Compare the effect of docetaxel and bevacizumab, in terms of objective response,&#xD;
           stabilization of disease, and progression-free survival, in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to disease stage.&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and&#xD;
           bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.&#xD;
&#xD;
        -  Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8&#xD;
           weeks for 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After the second course, patients with stable or responsive disease undergo modified radical&#xD;
      mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo&#xD;
      radiotherapy 5 days a week for 7 weeks.&#xD;
&#xD;
      Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV&#xD;
      over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every&#xD;
      21 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with estrogen and/or progesterone receptor-positive disease also receive oral&#xD;
      tamoxifen daily for 5 years beginning after the completion of chemotherapy. Post-menopausal&#xD;
      patients may receive oral anastrozole once daily for 5 years instead of tamoxifen.&#xD;
&#xD;
      Patients are followed at 3, 6, and 12 months, every 6 months for 4 years, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the ability of bevacizumab and docetaxel to reduce microvessel density and induce apoptosis of endothelial and tumor cells.</measure>
    <time_frame>weeks 8 and 17</time_frame>
    <description>The primary outcome measure is the difference in change in biologic parameters between the two arms. Tumor biopsies are required to perform pre- and post-treatment tumor microvessel density determination, apoptosis by TUNEL assay, proliferation markers by immunohistochemistry(e.g. PCNA, Ki-67), and expression of nuclear clusterin/XIP8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with objective response</measure>
    <time_frame>5 years</time_frame>
    <description>Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combine bevacizumab and docetaxel.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.</description>
    <arm_group_label>Combine bevacizumab and docetaxel.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Combine bevacizumab and docetaxel.</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Combine bevacizumab and docetaxel.</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.&#xD;
Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Combine bevacizumab and docetaxel.</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.</description>
    <arm_group_label>Combine bevacizumab and docetaxel.</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.&#xD;
Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Combine bevacizumab and docetaxel.</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.</description>
    <arm_group_label>Combine bevacizumab and docetaxel.</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
               -  Stage IIIA or IIIB&#xD;
&#xD;
               -  Stage IV if patient has clinical evidence of locally advanced breast cancer only&#xD;
&#xD;
               -  Inoperable disease&#xD;
&#xD;
          -  Prior carcinoma in situ of the breast or bilateral breast cancer is allowed&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen and progesterone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female or male&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal (no greater than 2 times upper limit of normal [ULN] in patients with&#xD;
             an inherited disorder)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  INR and PTT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No proteinuria or clinically significant renal impairment&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 45% by echocardiogram or MUGA scan&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No inadequately controlled hypertension&#xD;
&#xD;
          -  No history of deep vein thrombosis or other thromboses&#xD;
&#xD;
          -  No clinically significant peripheral artery disease&#xD;
&#xD;
          -  No arterial thromboembolic event within the past 6 months including the following:&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancy within the past 10 years except inactive&#xD;
             nonmelanoma skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other uncontrolled concurrent illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No non-healing wounds&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No prior allergic reaction to compounds of similar chemical or biological composition&#xD;
             to bevacizumab, docetaxel, polysorbate 80 (Tween) formulations, or other agents used&#xD;
             in this study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent cytokines during docetaxel/bevacizumab administration&#xD;
&#xD;
               -  Concurrent cytokines during doxorubicin/cyclophosphamide administration allowed&#xD;
                  at the discretion of the treating physician&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior hormonal therapy (e.g., tamoxifen) allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy to affected breast allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  More than 28 days since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 10 days since prior thrombolytic agents&#xD;
&#xD;
          -  At least 10 days since prior full-dose oral or parenteral anticoagulants except to&#xD;
             maintain patency of permanent indwelling IV catheters&#xD;
&#xD;
          -  Concurrent warfarin allowed provided INR is less than 1.5&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed for osseous metastases provided they are not&#xD;
             initiated on day 1 of cycle 1&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent full-dose oral or parenteral anticoagulants except to maintain patency&#xD;
             of permanent indwelling IV catheters&#xD;
&#xD;
          -  No concurrent thrombolytic agents&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Silverman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Southwest</name>
      <address>
        <city>Middleburgh Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Chagrin Highlands</name>
      <address>
        <city>Orange Village</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Green Road</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Westlake</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 14, 2013</last_update_submitted>
  <last_update_submitted_qc>June 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

